The glucose-raising effect of glucagon is counterbalanced by the strong glucose-lowering effects of the GLP-1 receptor component
The dose-response relationship is clear and steep: 12mg produced the most weight loss in both Phase 2 (24.2%) and Phase 3 (28.7%), followed by 8mg (22.8% in Phase 2) and 4mg (17.1% in Phase 2)
Some compounders also use chemically distinct salt forms, such as semaglutide sodium, which have not been proven safe and effective in humans
This will often reduce heart palpitations
Commonly Reported Side Effects Many Saxenda users experience gastrointestinal symptoms, especially early in treatment: nausea vomiting diarrhea constipation abdominal pain bloating fatigue dizziness decreased appetite For some patients, these symptoms persist or worsen over time
What specific risks must be emphasized when counseling high-risk patients about GLP-1 therapy, and how do you document this patient education/ informed consent